A Phase 1 interventional study of Drug: PF-07817883 in Healthy, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-30.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to estimate the oral bioavailability of 3 new formulations of PF-07817883 (test) relative to reference tablet formulation in healthy adult participants under fasted conditions. The study will also assess the safety and tolerability of test and reference tablet formulations in healthy adult participants.
This is a Phase 1, open-label, randomized, 4-period, 4-sequence crossover study in healthy adult participants evaluating the rBA of 3 new PF-07817883 test oral formulation(s) compared to PF-07817883 reference oral formulation. Approximately 12 participants will be enrolled in this study with approximately equal number of participants randomized to 1 of 4 sequences.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single oral dose of PF-07817883 tablet under fasted condition
Drug: Drug: PF-07817883
Single oral dose of PF-07817883 tablet under fasted condition
Drug: Drug: PF-07817883
Single oral dose of PF-07817883 tablet under fasted condition
Drug: Drug: PF-07817883
Single oral dose of PF-07817883 tablet under fasted condition
Drug: Drug: PF-07817883
PF-07817883 tablet
Maximum Observed Plasma Concentration (Cmax) of PF-07817883
Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post-dose on Day 1 of each treatment period
Area Under the Concentration-time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of PF-07817883
Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post-dose on Day 1 of each treatment period
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. Treatment-emergent are events between first dose of study treatment and up to 28-35 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
Time frame: From start of study treatment (Day 1) up to 28-35 days after last dose of study treatment (maximum up to 47 days)
Number of Participants With Laboratory Test Abnormalities
Laboratory parameters included hematology (eosinophils/leukocytes \[%\] greater than \[\>\] 1.2\*upper limit of normal), and urinalysis (urine hemoglobin and leukocyte esterase greater than or equal \[\>=\] to 1).
Time frame: From start of study treatment (Day 1) up to last dose of study treatment (maximum up to 12 days)
Number of Participants With Clinically Significant Abnormality in Vital Signs
Vital signs included diastolic blood pressure (DBP), systolic blood pressure (SBP) and pulse rate (PR) were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value less than (\<) 90 millimeters of mercury (mmHg), change from baseline greater than or equal to (\>=) 30 mmHg increase, change from baseline \>=30 mmHg decrease; DBP: value \<50 mmHg, change from baseline \>=20 mmHg increase, change from baseline \>=20 mmHg decrease; PR: value \<40 beats per minute (bpm), value greater than (\>) 120 bpm.
Time frame: From start of study treatment (Day 1) up to last dose of study treatment (maximum up to 12 days)
Number of Participants With Clinically Significant Abnormality in Electrocardiogram (ECG)
Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest. Criteria were PR interval (\>=300 millisecond \[msec\], percent \[%\] change from baseline \>=25 to 50%), QRS duration (\>=140 msec, %change from baseline \>=50%), corrected QT interval using Fridericia's formula (QTcF) (\>500 msec, %change from baseline \>60 msec, 450 msec\<value less than equal to \[\<=\] 480 msec, 480 msec\<value\<=500 msec, 30 msec\<=change\<=60 msec).
Time frame: From start of study treatment (Day 1) up to last dose of study treatment (maximum up to 12 days)
A total of 12 participants were enrolled and randomized in this study to 1 of the 4 study treatment sequences.
| Milestone | Treatment Sequence 1: A Then B Then C Then D | Treatment Sequence 2: B Then D Then A Then C | Treatment Sequence 3: C Then A Then D Then B | Treatment Sequence 4: D Then C Then B Then A |
|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 |
| Treated | 3 | 3 | 3 | 3 |
| Completed | 3 | 3 | 2 | 3 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| Milestone | Treatment Sequence 1: A Then B Then C Then D | Treatment Sequence 2: B Then D Then A Then C | Treatment Sequence 3: C Then A Then D Then B | Treatment Sequence 4: D Then C Then B Then A |
|---|---|---|---|---|
| Started | 3 | 3 | 2 | 3 |
| Completed | 3 | 3 | 2 | 3 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1: A Then B Then C Then D | Treatment Sequence 2: B Then D Then A Then C | Treatment Sequence 3: C Then A Then D Then B | Treatment Sequence 4: D Then C Then B Then A |
|---|---|---|---|---|
| Started | 3 | 3 | 2 | 3 |
| Completed | 3 | 3 | 2 | 3 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1: A Then B Then C Then D | Treatment Sequence 2: B Then D Then A Then C | Treatment Sequence 3: C Then A Then D Then B | Treatment Sequence 4: D Then C Then B Then A |
|---|---|---|---|---|
| Started | 3 | 3 | 2 | 3 |
| Completed | 3 | 3 | 2 | 3 |
| Not completed | 0 | 0 | 0 | 0 |
| nanogram per milliliter (ng/mL) | Treatment A: PF-07817883 300 mg Reference Formulation | Treatment B: PF-07817883 300 mg Test Formulation 1 | Treatment C: PF-07817883 300 mg Test Formulation 2 | Treatment D: PF-07817883 300 mg Test Formulation 3 |
|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of PF-07817883 | 2308 ± 39 | 2579 ± 28 | 4266 ± 40 | 3566 ± 34 |
| nanogram*hour per milliliter (ng*hr/mL) | Treatment A: PF-07817883 300 mg Reference Formulation | Treatment B: PF-07817883 300 mg Test Formulation 1 | Treatment C: PF-07817883 300 mg Test Formulation 2 | Treatment D: PF-07817883 300 mg Test Formulation 3 |
|---|---|---|---|---|
| Area Under the Concentration-time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of PF-07817883 | 17660 ± 35 | 18200 ± 22 | 21040 ± 36 | 21510 ± 33 |
An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. Treatment-emergent are events between first dose of study treatment and up to 28-35 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
| Participants | Treatment A: PF-07817883 300 mg Reference Formulation | Treatment B: PF-07817883 300 mg Test Formulation 1 | Treatment C: PF-07817883 300 mg Test Formulation 2 | Treatment D: PF-07817883 300 mg Test Formulation 3 |
|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 2 | 2 | 3 | 2 |
Laboratory parameters included hematology (eosinophils/leukocytes \[%\] greater than \[\>\] 1.2\*upper limit of normal), and urinalysis (urine hemoglobin and leukocyte esterase greater than or equal \[\>=\] to 1).
| Participants | Treatment A: PF-07817883 300 mg Reference Formulation | Treatment B: PF-07817883 300 mg Test Formulation 1 | Treatment C: PF-07817883 300 mg Test Formulation 2 | Treatment D: PF-07817883 300 mg Test Formulation 3 |
|---|---|---|---|---|
| Number of Participants With Laboratory Test Abnormalities | 1 | 0 | 1 | 2 |
Vital signs included diastolic blood pressure (DBP), systolic blood pressure (SBP) and pulse rate (PR) were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value less than (\<) 90 millimeters of mercury (mmHg), change from baseline greater than or equal to (\>=) 30 mmHg increase, change from baseline \>=30 mmHg decrease; DBP: value \<50 mmHg, change from baseline \>=20 mmHg increase, change from baseline \>=20 mmHg decrease; PR: value \<40 beats per minute (bpm), value greater than (\>) 120 bpm.
| Participants | Treatment A: PF-07817883 300 mg Reference Formulation | Treatment B: PF-07817883 300 mg Test Formulation 1 | Treatment C: PF-07817883 300 mg Test Formulation 2 | Treatment D: PF-07817883 300 mg Test Formulation 3 |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Abnormality in Vital Signs | 0 | 0 | 0 | 0 |
Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest. Criteria were PR interval (\>=300 millisecond \[msec\], percent \[%\] change from baseline \>=25 to 50%), QRS duration (\>=140 msec, %change from baseline \>=50%), corrected QT interval using Fridericia's formula (QTcF) (\>500 msec, %change from baseline \>60 msec, 450 msec\<value less than equal to \[\<=\] 480 msec, 480 msec\<value\<=500 msec, 30 msec\<=change\<=60 msec).
| Participants | Treatment A: PF-07817883 300 mg Reference Formulation | Treatment B: PF-07817883 300 mg Test Formulation 1 | Treatment C: PF-07817883 300 mg Test Formulation 2 | Treatment D: PF-07817883 300 mg Test Formulation 3 |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Abnormality in Electrocardiogram (ECG) | 0 | 0 | 0 | 0 |
Collected over From start of study treatment (Day 1) up to 28-35 days after last dose of study treatment (maximum up to 47 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A: PF-07817883 300 mg Reference Formulation | 0/11 (0%) | 0/11 (0%) | 2/11 (18.2%) |
| Treatment B: PF-07817883 300 mg Test Formulation 1 | 0/11 (0%) | 0/11 (0%) | 2/11 (18.2%) |
| Treatment C: PF-07817883 300 mg Test Formulation 2 | 0/12 (0%) | 0/12 (0%) | 3/12 (25%) |
| Treatment D: PF-07817883 300 mg Test Formulation 3 | 0/11 (0%) | 0/11 (0%) | 2/11 (18.2%) |
| Event | Treatment A: PF-07817883 300 mg Reference Formulation | Treatment B: PF-07817883 300 mg Test Formulation 1 | Treatment C: PF-07817883 300 mg Test Formulation 2 | Treatment D: PF-07817883 300 mg Test Formulation 3 |
|---|---|---|---|---|
| Lip dryGastrointestinal disorders | 0/11 | 1/11 | 0/12 | 0/11 |
| Vessel puncture site bruiseGeneral disorders | 1/11 | 0/11 | 0/12 | 0/11 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/11 | 1/11 | 0/12 | 0/11 |
| HeadacheNervous system disorders | 1/11 | 0/11 | 1/12 | 1/11 |
| HaematomaVascular disorders | 0/11 | 0/11 | 0/12 | 1/11 |
| LymphadenopathyBlood and lymphatic system disorders | 0/11 | 0/11 | 1/12 | 0/11 |
| NauseaGastrointestinal disorders | 0/11 | 0/11 | 1/12 | 0/11 |
| InfluenzaInfections and infestations | 0/11 | 0/11 | 1/12 | 0/11 |
| PolyuriaRenal and urinary disorders | 0/11 | 0/11 | 1/12 | 0/11 |
| HypertensionVascular disorders | 0/11 | 0/11 | 1/12 | 0/11 |
Safety analysis set included all participants randomly assigned to study treatment and who took at least 1 dose of study treatment in at least one treatment period. Participants were analyzed according to the product they actually received.
| Age, Continuous(Years) | Treatment Sequence 1: A Then B Then C Then D | Treatment Sequence 2: B Then D Then A Then C | Treatment Sequence 3: C Then A Then D Then B | Treatment Sequence 4: D Then C Then B Then A | Total |
|---|---|---|---|---|---|
| Mean (SD) | 58.7 ± 4.93 | 34.7 ± 3.06 | 41.3 ± 18.15 | 51.0 ± 21.28 | 46.4 ± 15.48 |
| Sex: Female, Male(Participants) | Treatment Sequence 1: A Then B Then C Then D | Treatment Sequence 2: B Then D Then A Then C | Treatment Sequence 3: C Then A Then D Then B | Treatment Sequence 4: D Then C Then B Then A | Total |
|---|---|---|---|---|---|
| Female | 1 | 1 | 0 | 1 | 3 |
| Male | 2 | 2 | 3 | 2 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Sequence 1: A Then B Then C Then D | Treatment Sequence 2: B Then D Then A Then C | Treatment Sequence 3: C Then A Then D Then B | Treatment Sequence 4: D Then C Then B Then A | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 0 | 1 |
| Not Hispanic or Latino | 3 | 3 | 2 | 3 | 11 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Treatment Sequence 1: A Then B Then C Then D | Treatment Sequence 2: B Then D Then A Then C | Treatment Sequence 3: C Then A Then D Then B | Treatment Sequence 4: D Then C Then B Then A | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 3 | 3 | 3 | 3 | 12 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Nov 2023 to primary completion in Jan 2024, 1 month.
Results were first posted in Jan 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibuzatrelvir